The simultaneous departure of three top executives and the wind-down of the legacy biotech business represent a near-total strategic reset. The new CFO's equity grants are contingent on board approval and share availability, which may signal limited authorized shares. Monitor the next periodic report for impairment charges and the company's updated business strategy. The stock is likely to face significant volatility and downward pressure as the market prices in execution risk and the loss of the biotech segment's revenue stream.
Price Chart
Executive Summary
AIxCrypto Holdings announced the immediate resignation of its Co-CEO, President, and CFO (effective June 20), the appointment of a new President/CFO (Jie Sheng) and two new directors, and the discontinuation and wind-down of its legacy biotechnology business. The simultaneous departure of three top executives and the abandonment of a core business segment signal a fundamental strategic pivot and significant organizational disruption.
Key Facts
- Co-CEO Kevin Richardson II resigned effective immediately on May 21, 2026.
- President Campbell Becher resigned effective immediately on May 21, 2026.
- CFO Koti Meka resigned as director immediately and as CFO effective June 20, 2026.
- Jie (Jay) Sheng appointed President and CFO, effective June 21, 2026, with an annual base salary of $400,000 and eligibility for a discretionary bonus of up to $200,000.
- Jerry Wang (current Co-CEO) appointed to the Board of Directors; he is a nephew of Yueting Jia, CEO of the company's majority shareholder.
- Chen Shi appointed as an independent director; expected to chair the Audit Committee.
- Board approved the discontinuation and structured wind-down of the legacy biotechnology business segment; financial impact is still being evaluated.
- The company is a $26M market cap micro-cap with a history of name changes (formerly Qualigen Therapeutics, Ritter Pharmaceuticals).
Financial Impact
Undisclosed — the company is still evaluating charges, asset impairments, and other costs from the biotech wind-down. New CFO compensation totals up to $600,000 annually in cash plus up to $520,000 in equity (RSUs/PSUs) subject to board approval and share availability.
Risk Factors
- Execution risk from simultaneous departure of Co-CEO, President, and CFO with no permanent CEO replacement named.
- Unquantified impairment charges and wind-down costs from the biotech segment could materially impact near-term financials.
- Potential Nasdaq compliance risk given micro-cap status and repeated corporate transformations.
- Related-party governance concerns: new director Jerry Wang is a nephew of the majority shareholder's CEO, and the company's former name changes suggest a history of restructuring.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-025670 |
| Exhibit: ex10-1.htm | 0001493152-26-025670 |
| Document: 0001493152-26-025670-index-headers.html | 0001493152-26-025670 |
| Document: 0001493152-26-025670-index.html | 0001493152-26-025670 |
| Document: 0001493152-26-025670.txt | 0001493152-26-025670 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 29, 2026 27d ago | 8-K | $1.03 | awaiting T+1 | — | — |
Sep 15, 2026 6w ago | EFFECT | $1.03 $0.9602 | ▲ +6.32% | ▲ +5.88% | — |
Sep 9, 2026 6w ago | S-1/A | $0.7058 $0.7402 | ▼ −4.87% | ▼ −5.47% | — |
Sep 3, 2026 7w ago | S-1/A | $0.7094 $0.6904 | ▲ +2.68% | ▲ +2.13% | — |
Aug 26, 2026 8w ago | 8-K | $0.8431 $0.7828 | ▼ −7.15% | ▼ −6.93% | — |
Aug 4, 2026 11w ago | Press Release | $0.7710 $0.8257 | ▲ +7.09% | ▲ +7.25% | — |
Jun 23, 2026 17w ago | 8-K | $1.19 $1.05 | ▼ −11.76% | ▼ −11.91% | — |
Jun 17, 2026 18w ago | 8-K | $1.46 $1.36 | ▲ +6.85% | ▲ +6.53% | — |
May 28, 2026 21w ago | 8-K | $1.28 $1.31 | ▼ −2.34% | ▼ −2.09% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers